

Sheet 1

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 3

-	Complete if Known				
	Application Number	10/673,629			
	Filing Date	September 29, 2003			
	First Named Inventor	Hector F. DeLuca			
	Art Unit	1616			
	Examiner Name				
	Attorney Docket Number	1256-00923			

			U. S. PATEN	T DOCUM			
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Ap	Name of Patentee or plicant of Cited Document	Pages, Columns, Lines, Who Relevant Passages or Relevant Figures Appear	ere ani
2 W		^{US-} 5,843,928	12-01-1998	DeLuca	a et al		_
EM		^{US-} 5,587,497	12-24-1996	DeLuca	a et al		
- 		US-	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				7
		US-		+	 		
		US-					_
		US-					
		US-		1			_
		US-		 			_
		US-					
		US-					
		US-		1			_
		US-		1			_
		US-					_
		US-					
		US-					
		US.					
		NG.					_
		US-					
		US-					_
			FOREIGN PATI	NT DOCI	MENTO		_
Examiner Initials*	Cite No.1	Foreign Patent Document	Pi	iblication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ
		Country Code ³ Number ⁴ Kind Code ⁵ (# known)		DD-YYYY		Or Relevant Figures Appear	1
							_

	FOREIGN PATENT DOCUMENTS									
Examine Initials*	Examiner Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages					
		Country Code ³ "Number ⁴ "Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ*				
						L				
	1									

Examiner Signature Date Considered 5/31/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with yest communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.dov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	der the Paperwork Red	duction A	Act of 1995, no persons a	required to respond to a collection of information unless it contains a valid OMB control nul C mpl te if Known			
Subsuit	Re for form 1449/PTO			Application Numb r	10/673,629		
INF	ORMATION	I DIS	SCLOSURE	Filing Date	September 29, 2003		
STA	ATEMENT E	3Y A	PPLICANT	First Named Inventor	Hector F. DeLuca		
	01			Art Unit	1616		
	(Use as many sh	98CS 85 (necessary)	Examiner Name			
Sheet	2	of	3	Attorney Docket Number	1256-00923		

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-iss number(s), publisher, city and/or country where published.						
4		The Merck Manual, Sixteenth Edition, 1992, pg. 1357.					
		Boris et al, "Relative Activities of Some Metabolites and Analogs of Cholecalciferol in Stimulation of Tibia Ash Weight in Chicks Otherwise Deprived of Vitamin D," Vitamin D Metabolites, Analogs and Bone Ash, 1976, pp. 194-198.					
		Hedlund et al, "Increased Incidence of Hip Fracture in Osteoporotic Women Treated with Sodium Fluoride," Journal of Bone and Mineral Research, Vol. 4, No. 2, 1989, pp. 223-225.					
		Holick et al, Harrison's Principle of Internal Medicine, 13th Ed. 1994, pp. 2137-2151.					
		Jensen et al, "Treatment of Post Menopausal Osteoporosis, A Controlled Therapeutic Trial Comparing Oestrogen/Gestagen, 1,25-Dihydroxy-Vitamin D-3 and Calcium," Clinical Endocrinology, 16, 1982, pp. 515-524					
		Meunier, "Evidence-Based Medicine and Osteoporosis: A Comparison of Fracture Risk Reduction Data from Osteoporosis Randomised Clinical Trials," IJCP, Vol. 53, No. 2, March, 1999.					
		Nordin et al, "The Metabolic Basis of Osteoporosis," Osteoporosis: Physiological Basis, Assessment, and Treatment, Elsevier Science Publishing Co., Inc., 1990, pp.23-36.					
		Ott et al, "Calcitriol Treatment is not Effective in Postmenopausal Osteoporosis," Annals of Internal Medicine, Vol. 110, No. 4, February 15, 1989, pp. 267-274.					
		Peck, "The Pathogenesis of Postmenopausal Osteoporosis," Osteoporosis: Physiological Basis, Assessment, and Treatment, Elsevier Science Publishing Co., Inc., 1990, pp. 3-6.					
SM		Riggs et al, "Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures without Commensurate Increases in Bone Density," Journal of Bone and Mineral Research, Vol. 17, No. 1, 2002, pp. 11-13.					

Examiner		-11	Date	1 1.	, /
Signature	/and	~ 14	Considered	1 3/3	1/04
*EYAMINED: Ini	Hal if reference considered when	han as not ditation in in conform	and with MDED COO. Describes thereigh	-14-41 M4 I	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (options). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

			ct of 1995, no persons ar	re required to respond to a collection of information unless it contains a valid OMB control numbe C mpl te if Known			
SUBSTILI	te for form 1449/PT	0		Application Number	10/673,629		
INFO	DRMATIC	N DIS	CLOSURE	Filing Date	September 29, 2003		
STA	TEMENT	BYA	PPLICANT	First Named Inventor	Hector F. DeLuca		
				Art Unit	1616		
	(Use as many	eneers as r	iecessary)	Examiner Name			
Sheet	3	of	3	Attorney Docket Number	1256-00923		

	No.¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
811		Riggs et al, "Causes of Age-Related Bone Loss and Fractures," Osteoporosis: Physiological Basis, Assessment, and Treatment, 1990, pp. 7-16.	
	_	Christensen, Abstract PMID: 6795047, "Effect of 1,25-Dihydroxy-Vitamin D3 in Itself or Combined with Hormone Treatment in Prevent Postmenopausal Osteoporosis," Eur. J. Clin. Invest., August 11, 1981, Vol. 11, No. 4.	
		Klein, "Nutritional Rickets and Osteomalacia," Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 1996, pp. 301-305.	
		Kleerekoper, "Treatment of Osteoporosis with Sodium Fluoride Alternating with Calcium and Vitamin D," Osteoporosis: Recent Advances in Pathogenesis and Treatment, 1981, pp. 441-448.	
		Sarkar, "Relationships Between Bone Mineral Desnity and Incident Vertebral Fracture Risk with Raloxifene Therapy," Journal of Bone and Mineral Research, Vol. 17, No. 1, 2002, pp. 1-10.	
	_	Cummings et al, "Improvement in Spine Bone Desity and Reduction in Risk of Vertebral Fractures During Treatment with Antiresorptive Drugs," The American Journal of Medicine, Vol. 112, 2002, pp. 281-289.	
		Sudhaker Rao et al, "Metabolic Bone Disease in Gastrointestinal Hepatobiliary, and Pancreatic Disorders," Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 1996, pp. 306-311.	
		Watts et al, "Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis," The New England Journal of Medicine, Vol. 323, No. 2, July 12, 1990, pp. 73-79.	
671		Harris, "Four-Year Study of Intermittent Cyclic Etidronate Treatment of Postmenopausal Osteoporosis: Three Years of Blinded Therapy Followed by One Year of Open Therapy," The American Journal of Medicine, Vol. 95, December 1993, pp. 557-567.	

		<u> </u>		
Examiner			Date	L/21/21/
Signature	1/00/		Considered	1/3//04

^{**}EXAMINER: Initial if reference considered, whether or not citytion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to explicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: